according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Fluazuron / Abamectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions :

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

+1-908-423-6000

# **SECTION 2: Hazards identification**

# 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Flammable liquids, Category 3 H226: Flammable liquid and vapour.

Acute toxicity, Category 4 H332: Harmful if inhaled. Skin irritation, Category 2 H315: Causes skin irritation.

Eye irritation, Category 2 H319: Causes serious eye irritation.

Skin sensitisation, Category 1

Germ cell mutagenicity, Category 2

Reproductive toxicity, Category 1B

Specific target organ toxicity - single ex
H317: May cause an allergic skin reaction.

H341: Suspected of causing genetic defects.

H360D: May damage the unborn child.

H336: May cause drowsiness or dizziness.

posure, Category 3

Specific target organ toxicity - single ex-

posure, Category 3

Specific target organ toxicity - repeated

exposure, Category 2

Short-term (acute) aquatic hazard, Cate-

gory 1

Long-term (chronic) aquatic hazard, Cat-

H335: May cause respiratory irritation.

H373: May cause damage to organs through pro-

longed or repeated exposure.

H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

egory 1 effects.

# 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms









Signal word : Danger

Hazard statements : H226 Flammable liquid and vapour.

H315 Causes skin irritation.

H317 May cause an allergic skin reaction.H319 Causes serious eye irritation.

H332 Harmful if inhaled.

H335 May cause respiratory irritation.
 H336 May cause drowsiness or dizziness.
 H341 Suspected of causing genetic defects.

H360D May damage the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P210 Keep away from heat, hot surfaces, sparks, open

flames and other ignition sources. No smoking. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Hazardous components which must be listed on the label:

Propan-2-ol

N-Methyl-2-pyrrolidone

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

Restricted to professional users.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Vapours may form explosive mixture with air.

# **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

| Chemical name  | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification  | Concentration<br>(% w/w) |
|--|---|---|--------------------------|
| Propan-2-ol  | 67-63-0<br>200-661-7<br>603-117-00-0                  | Flam. Liq. 2; H225<br>Eye Irrit. 2; H319<br>STOT SE 3; H336   | >= 30 - < 50             |
| N-Methyl-2-pyrrolidone   | 872-50-4<br>212-828-1<br>606-021-00-7                 | Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 3; H335 ——— specific concentration limit STOT SE 3; H335 >= 10 %                         | >= 30 - < 50             |
| Fluazuron  | 86811-58-7  | Aquatic Acute 1; H400 Aquatic Chronic 1; H410 ——— M-Factor (Acute aquatic toxicity): 1.000 M-Factor (Chronic aquatic toxicity): 1.000                   | >= 2,5 - < 10            |
| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2<br>606-143-00-0                            | Acute Tox. 2; H300<br>Acute Tox. 1; H330<br>Acute Tox. 3; H311<br>Repr. 2; H361fd<br>STOT RE 1; H372<br>(Central nervous<br>system)<br>Aquatic Acute 1; | >= 1 - < 2,5             |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

| Version<br>8.0 |  | SDS Number:<br>803738-00028     | Date of last issue: 06.07.2020<br>Date of first issue: 12.07.2010  |                 |
|----------------|--|---------------------------------|--|-----------------|
|                |  |                                 | H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000  specific concentration limit STOT RE 1; H372 >= 5 % STOT RE 2; H373 0,5 - < 5 % |                 |
| oxabi          | abicyclo[4.1.0]hept-3-ylme<br>cyclo[4.1.0]heptane-3-<br>xylate | ethyl 7- 2386-87-0<br>219-207-4 | Skin Sens. 1; H317<br>Muta. 2; H341<br>STOT RE 2; H373<br>(nasal cavity)<br>Aquatic Chronic 3;<br>H412   | >= 1 - < 2,5    |
| 2,6-D          | i-tert-butyl-p-cresol  | 128-37-0<br>204-881-4           | Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1   | >= 0,1 - < 0,25 |

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

# 4.1 Description of first aid measures

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

: First Aid responders should pay attention to self-protection, Protection of first-aiders

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled If inhaled, remove to fresh air.

If not breathing, give artificial respiration.

If breathing is difficult, give oxygen.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes skin irritation.

May cause an allergic skin reaction. Causes serious eye irritation.

Harmful if inhaled.

May cause respiratory irritation. May cause drowsiness or dizziness. Suspected of causing genetic defects.

May damage the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

# 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

High volume water jet

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Do not use a solid water stream as it may scatter and spread

fire.

Flash back possible over considerable distance.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx) Chlorine compounds Fluorine compounds

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Remove all sources of ignition.

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Non-sparking tools should be used.

Soak up with inert absorbent material.

Suppress (knock down) gases/vapours/mists with a water

spray jet.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Use explosion-proof electrical, ventilating and lighting equip-

ment.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Non-sparking tools should be used. Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Keep away from heat, hot surfaces, sparks, open flames and

other ignition sources. No smoking.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

# 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in

accordance with the particular national regulations. Keep

away from heat and sources of ignition.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 80.09.2024 80.09.2024 Date of first issue: 12.07.2016

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides Flammable solids Pyrophoric liquids Pyrophoric solids

Self-heating substances and mixtures

Substances and mixtures, which in contact with water, emit

flammable gases

Explosives Gases

Very acutely toxic substances and mixtures

7.3 Specific end use(s)

Specific use(s) : No data available

# **SECTION 8: Exposure controls/personal protection**

# 8.1 Control parameters

# **Occupational Exposure Limits**

| Components  | CAS-No.  | Value type (Form of exposure)   | Control parameters            | Basis         |  |  |
|-------------|--|---|-------------------------------|---------------|--|--|
| Propan-2-ol | 67-63-0  | TWA   | 100 ppm                       | FOR-2011-     |  |  |
| <u>'</u>    |  |   | 245 mg/m3                     | 12-06-1358    |  |  |
| N-Methyl-2- | 872-50-4   | TWA   | 14,4 mg/m3                    | FOR-2011-     |  |  |
| pyrrolidone |  |   |                               | 12-06-1358    |  |  |
|             |  | nation: Substances c<br>bed through the skin.                                     | onsidered to be reprotoxic, C | hemicals that |  |  |
|             |  | STEL  | 20 ppm                        | FOR-2011-     |  |  |
|             |  |   | 80 mg/m3                      | 12-06-1358    |  |  |
|             | Further inform   | nation: Substances c  | onsidered to be reprotoxic, C | hemicals that |  |  |
|             | can be absort  | bed through the skin.   | •                             |               |  |  |
|             |  | TWA   | 10 ppm                        | 2009/161/EU   |  |  |
|             |  |   | 40 mg/m3                      |               |  |  |
|             | Further inform   | Further information: Identifies the possibility of significant uptake through the |                               |               |  |  |
|             | skin, Indicative   |   |                               |               |  |  |
|             |  | STEL  | 20 ppm                        | 2009/161/EU   |  |  |
|             |  |   | 80 mg/m3                      |               |  |  |
|             | Further information: Identifies the possibility of significant uptake skin, Indicative |   | e through the                 |               |  |  |
|             |  | TWA   | 10 ppm                        | 2004/37/EC    |  |  |
|             |  |   | 40 mg/m3                      |               |  |  |
|             | Further inform   | Further information: Skin, Carcinogens or mutagens                                |                               |               |  |  |
|             |  | STEL  | 20 ppm                        | 2004/37/EC    |  |  |
|             |  |   | 80 mg/m3                      |               |  |  |
|             | Further information: Skin, Carcinogens or mutagens                                     |   |                               |               |  |  |
| Fluazuron   | 86811-58-7   | TWA   | 60 μg/m3 (OEB 3)              | Internal      |  |  |
|             |  | Wipe limit  | 600 µg/ 100cm2                | Internal      |  |  |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2 | TWA        | 15 μg/m3 (OEB 3)           | Internal |
|--|------------|------------|----------------------------|----------|
|  |            | Wipe limit | 150 µg/100 cm <sup>2</sup> | Internal |

# Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

|   | <u> </u>  |                 | · · ·                        |                      |
|---|-----------|-----------------|------------------------------|----------------------|
| Substance name  | End Use   | Exposure routes | Potential health effects     | Value                |
| N-Methyl-2-<br>pyrrolidone  | Workers   | Inhalation      | Long-term systemic effects   | 14,4 mg/m3           |
|   | Workers   | Inhalation      | Long-term local ef-<br>fects | 40 mg/m3             |
|   | Workers   | Skin contact    | Long-term systemic effects   | 4,8 mg/kg<br>bw/day  |
|   | Consumers | Inhalation      | Long-term systemic effects   | 3,6 mg/m3            |
|   | Consumers | Inhalation      | Long-term local effects      | 4,5 mg/m3            |
|   | Consumers | Skin contact    | Long-term systemic effects   | 2,4 mg/kg<br>bw/day  |
|   | Consumers | Ingestion       | Long-term systemic effects   | 0,85 mg/kg<br>bw/day |
| 7-<br>Oxabicy-<br>clo[4.1.0]hept-3-<br>ylmethyl 7-<br>oxabicy-<br>clo[4.1.0]heptane-3-<br>carboxylate | Workers   | Inhalation      | Long-term systemic effects   | 0,18 mg/m3           |
|   | Workers   | Inhalation      | Long-term local effects      | 0,18 mg/m3           |
|   | Workers   | Skin contact    | Long-term systemic effects   | 0,05 mg/kg<br>bw/day |
| Propan-2-ol   | Workers   | Inhalation      | Long-term systemic effects   | 500 mg/m3            |
|   | Workers   | Skin contact    | Long-term systemic effects   | 888 mg/kg<br>bw/day  |
|   | Consumers | Inhalation      | Long-term systemic effects   | 89 mg/m3             |
|   | Consumers | Skin contact    | Long-term systemic effects   | 319 mg/kg<br>bw/day  |
|   | Consumers | Ingestion       | Long-term systemic effects   | 26 mg/kg<br>bw/day   |
| 2,6-Di-tert-butyl-p-<br>cresol  | Workers   | Inhalation      | Long-term systemic effects   | 3,5 mg/m3            |
|   | Workers   | Dermal          | Long-term systemic effects   | 0,5 mg/kg<br>bw/day  |
|   | Consumers | Inhalation      | Long-term systemic effects   | 0,86 mg/m3           |
|   | Consumers | Dermal          | Long-term systemic           | 0,25 mg/kg           |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

|           |           | effects            | bw/day     |
|-----------|-----------|--------------------|------------|
| Consumers | Ingestion | Long-term systemic | 0,25 mg/kg |
|           |           | effects            | bw/day     |

# Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

| Environmental Compartment Value |  |
|---------------------------------|--|
| Fresh water                     | 0,25 mg/l  |
| Freshwater - intermittent       | 5 mg/l   |
| Marine water                    | 0,025 mg/l   |
| Sewage treatment plant          | 10 mg/l  |
| Fresh water sediment            | 1,09 mg/kg dry   |
|                                 | weight (d.w.)  |
| Marine sediment                 | 1,09 mg/kg dry   |
|                                 | weight (d.w.)  |
| Soil                            | 0,07 mg/kg dry   |
|                                 | weight (d.w.)  |
| Fresh water                     | 0,024 mg/l   |
| Freshwater - intermittent       | 0,24 mg/l  |
| Marine water                    | 0,0024 mg/l  |
| Sewage treatment plant          | 19,5 mg/l  |
| Fresh water sediment            | 0,211 mg/kg dry  |
|                                 | weight (d.w.)  |
| Marine sediment                 | 0,0211 mg/kg dry   |
|                                 | weight (d.w.)  |
| Soil                            | 0,0282 mg/kg dry   |
|                                 | weight (d.w.)  |
| Fresh water                     | 140,9 mg/l   |
| Marine water                    | 140,9 mg/l   |
| Intermittent use/release        | 140,9 mg/l   |
|                                 | 2251 mg/l  |
| Fresh water sediment            | 552 mg/kg dry  |
|                                 | weight (d.w.)  |
| Marine sediment                 | 552 mg/kg dry  |
|                                 | weight (d.w.)  |
| Soil                            | 28 mg/kg dry   |
|                                 | weight (d.w.)  |
| Oral (Secondary Poisoning)      | 160 mg/kg food   |
| Fresh water                     | 0,199 µg/l   |
| Intermittent use/release        | 0,02 μg/l  |
|                                 | 0,02 μg/l  |
|                                 | 0,17 mg/l  |
|                                 | 0,0996 mg/kg dry   |
|                                 | weight (d.w.)  |
| Marine sediment                 | 0,00996 mg/kg  |
|                                 | dry weight (d.w.)  |
| Soil                            | 0,04769 mg/kg  |
|                                 | dry weight (d.w.)  |
| Oral (Secondary Poisoning)      | 8,33 mg/kg food  |
|                                 | Fresh water Freshwater - intermittent Marine water Sewage treatment plant Fresh water sediment  Marine sediment  Soil  Fresh water  Freshwater - intermittent Marine water Sewage treatment plant Fresh water sediment  Marine sediment  Soil  Fresh water  Marine sediment  Soil  Fresh water  Marine water Intermittent use/release Sewage treatment plant Fresh water sediment  Marine sediment  Soil  Oral (Secondary Poisoning) Fresh water |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

#### 8.2 Exposure controls

#### **Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Use explosion-proof electrical, ventilating and lighting equipment.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving. Take note that the product is flam-

mable, which may impact the selection of hand protection.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

# **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : 28 °C

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

# **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Flammable liquid and vapour.

Vapours may form explosive mixture with air. Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

# **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

**Acute toxicity** 

Harmful if inhaled.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 2,06 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

**Components:** 

Propan-2-ol:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Acute inhalation toxicity : LC50 (Rat): > 25 mg/l

Exposure time: 6 h
Test atmosphere: vapour

Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4.150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,1 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5.000 mg/kg

Fluazuron:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 6,0 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg

Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0,023 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2.000 mg/kg

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Acute oral toxicity : LD50 (Rat, male): > 2.959 - 5.000 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): >= 5,19 mg/l

Exposure time: 4 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Test atmosphere: dust/mist

Method: OECD Test Guideline 436

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:

Propan-2-ol:

Species : Rabbit

Result : No skin irritation

N-Methyl-2-pyrrolidone:

Result : Skin irritation

Fluazuron:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : No skin irritation

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 404

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Result : No skin irritation

Remarks : Based on data from similar materials

# Serious eye damage/eye irritation

Causes serious eye irritation.

#### **Components:**

#### Propan-2-ol:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

# N-Methyl-2-pyrrolidone:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

#### Fluazuron:

Species : Rabbit

Method : OECD Test Guideline 405

Result : Mild eye irritation

#### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : Mild eye irritation

### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

### 2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Remarks : Based on data from similar materials

# Respiratory or skin sensitisation

# Skin sensitisation

May cause an allergic skin reaction.

# Respiratory sensitisation

Not classified based on available information.

#### **Components:**

# Propan-2-ol:

Test Type : Buehler Test Exposure routes : Skin contact

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

N-Methyl-2-pyrrolidone:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : negative

Remarks : Based on data from similar materials

Fluazuron:

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximisation Test Exposure routes : Skin contact

Result : Not a skin sensitizer.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : positive

Assessment : Probability or evidence of skin sensitisation in humans

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact Species : Humans Result : negative

Germ cell mutagenicity

Suspected of causing genetic defects.

**Components:** 

Propan-2-ol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion Method: OECD Test Guideline 474

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Hamster

Application Route: Ingestion Method: OECD Test Guideline 475

Result: negative

Fluazuron:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA Repair

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Cytogenetic assay

Species: Hamster Result: equivocal

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Test system: Chinese hamster lung cells

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Result: positive

Test Type: In vitro sister chromatid exchange assay in mam-

malian cells Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: positive

Genotoxicity in vivo : Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 486

Result: negative

Test Type: Micronucleus test

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Transgenic rodent somatic cell gene mutation as-

say

Species: Mouse

Application Route: Ingestion

Method: OECD Test Guideline 488

Result: positive

Germ cell mutagenicity- As-

sessment

Positive result(s) from in vivo mammalian somatic cell muta-

genicity tests.

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

### Carcinogenicity

Not classified based on available information.

#### **Components:**

# Propan-2-ol:

Species : Rat

Application Route : inhalation (vapour)

Exposure time : 104 weeks

Method : OECD Test Guideline 451

Result : negative

#### N-Methyl-2-pyrrolidone:

Species: RatApplication Route: IngestionExposure time: 2 YearsResult: negative

Species : Rat

Application Route : inhalation (vapour)

Exposure time : 2 Years
Result : negative

#### Fluazuron:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : negative

Species: MouseApplication Route: IngestionExposure time: 2 YearsResult: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

#### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

# 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Mouse
Application Route : Skin contact
Exposure time : 29 Months
Result : negative

#### 2,6-Di-tert-butyl-p-cresol:

Species: RatApplication Route: IngestionExposure time: 22 MonthsResult: negative

# Reproductive toxicity

May damage the unborn child.

#### **Components:**

#### Propan-2-ol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

**Application Route: Ingestion** 

Result: negative

Effects on foetal develop: Test Type: Embryo-foetal development

ment Species: Rat

Application Route: Ingestion

Result: negative

#### N-Methyl-2-pyrrolidone:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Species: Rat

Effects on foetal develop- : Test Type: Embryo-foetal development

ment

Application Route: Ingestion

Method: OECD Test Guideline 414

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Result: positive

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: inhalation (vapour)

Result: positive

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: positive

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

Fluazuron:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion Method: OECD Test Guideline 414

Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0,12 mg/kg body

weight

Result: Fetotoxicity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight Developmental Toxicity: NOAEL: 0,2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects, Reduced embryonic

surviva

Remarks: Adverse developmental effects were observed

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1,6 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal experi-

ments.

# 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 414

Result: negative

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

#### STOT - single exposure

May cause respiratory irritation. May cause drowsiness or dizziness.

# Components:

Propan-2-ol:

Assessment : May cause drowsiness or dizziness.

N-Methyl-2-pyrrolidone:

Assessment : May cause respiratory irritation.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

#### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Exposure routes : Ingestion
Target Organs : nasal cavity

Assessment : Shown to produce significant health effects in animals at con-

centrations of >10 to 100 mg/kg bw.

### 2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.

#### Repeated dose toxicity

#### **Components:**

#### Propan-2-ol:

Species : Rat NOAEL : 12,5 mg/l

Application Route : inhalation (vapour)

Exposure time : 104 Weeks

#### N-Methyl-2-pyrrolidone:

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Method : OECD Test Guideline 408

 Species
 : Rat

 NOAEL
 : 0,5 mg/l

 LOAEL
 : 1 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 96 Days

Method : OECD Test Guideline 413

Species: RabbitNOAEL: 826 mg/kgLOAEL: 1.653 mg/kgApplication Route: Skin contactExposure time: 20 Days

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Fluazuron:

Species Rat

LÖAEL 240 mg/kg LOAEL
Application Route
Exposure time
Target Organs Ingestion 13 Weeks

Liver, Thyroid, Pituitary gland Target Organs

Species Rat NOAEL 10 mg/kg LOAEL 100 mg/kg Application Route Skin contact Exposure time : 3 Weeks

: Dog Species NOAEL : 7,5 mg/kg LOAEL : 110 mg/kg Application Route : Ingestion Exposure time : 52 Weeks Target Organs Liver

#### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species Rat Species
NOAEL
Application Route
Exposure time 1,5 mg/kg : Oral : 24 Months

: Central nervous system

Symptoms Tremors, ataxia

Species
NOAEL
Application Route
Typosure time
Typosure time Species Mouse 4,0 mg/kg : Oral : 24 Months

: Central nervous system

Symptoms Tremors, ataxia

Species Dog

NOAEL 0,25 mg/kg LOAEL : 0,5 mg/kg Application Route
Exposure time
Target Organs : Oral : 53 Weeks

: Central nervous system Symptoms Tremors, weight loss Remarks : mortality observed

Species Monkey NOAEL 1,0 mg/kg Application Route Oral Exposure time 14 Weeks

Target Organs : Central nervous system

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

#### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species Rat 5 mg/kg NOAEL OAEL 50 mg/kg Application Route Ingestion 90 Days Exposure time

**OECD Test Guideline 408** Method

#### 2,6-Di-tert-butyl-p-cresol:

Species Rat NOAEL 25 mg/kg Application Route Ingestion Exposure time 22 Months

#### **Aspiration toxicity**

Not classified based on available information.

#### 11.2 Information on other hazards

### **Endocrine disrupting properties**

#### **Product:**

Assessment The substance/mixture does not contain components consid-

> ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### **Components:**

#### N-Methyl-2-pyrrolidone:

Skin contact Symptoms: Skin irritation

#### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion Symptoms: May cause, Tremors, Diarrhoea, central nervous

system effects, Salivation, tearing

# **SECTION 12: Ecological information**

# 12.1 Toxicity

#### Components:

#### Propan-2-ol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9.640 mg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 10.000 mg/l

Exposure time: 24 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1.050 mg/l

Exposure time: 16 h

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 1.000 mg/l

Exposure time: 24 h Method: DIN 38412

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50 : > 600 mg/l

Exposure time: 30 min Method: ISO 8192

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 12,5 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Fluazuron:

Toxicity to fish : LC50 (Cyprinus carpio (Carp)): > 9,1 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia sp. (water flea)): 0,0006 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

NOEC (Raphidocelis subcapitata (freshwater green alga)):

27,9 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox- :

icity)

1.000

M-Factor (Chronic aquatic

toxicity)

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

1.000

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3,2 μg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9,6 µg/l

Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l

Exposure time: 96 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

LC50 (Cyprinus carpio (Carp)): 42 μg/l

Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0,022 µg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0,34 μg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 100

mg/

Exposure time: 72 h

M-Factor (Acute aquatic tox- :

icity)

10.000

Toxicity to microorganisms : EC50 : > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,52 μg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,03 µg/l

Exposure time: 21 d

Species: Daphnia magna (Water flea)

NOEC: 0,0035 µg/l Exposure time: 28 d

Species: Mysidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic

toxicity)

10.000

# 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 24 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 40 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Raphidocelis subcapitata (freshwater green alga)): >

110 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

NOEC (Raphidocelis subcapitata (freshwater green alga)): 30

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC10 (activated sludge): 409 mg/l Toxicity to microorganisms

Exposure time: 3 h

Method: OECD Test Guideline 209

2,6-Di-tert-butyl-p-cresol:

LC50 (Danio rerio (zebra fish)): > 0,57 mg/l Toxicity to fish

Exposure time: 96 h

Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0,24

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

Toxicity to microorganisms EC50: > 10.000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,053 mg/l Exposure time: 30 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 210

Toxicity to daphnia and other: aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,316 mg/l

Exposure time: 21 d

Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic

toxicity)

# 12.2 Persistence and degradability

# **Components:**

Propan-2-ol:

Biodegradability Result: rapidly degradable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

BOD/COD : BOD: 1,19 (BOD5)

COD: 2,23 BOD/COD: 53 %

N-Methyl-2-pyrrolidone:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 73 % Exposure time: 28 d

Method: OECD Test Guideline 301C

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 71 % Exposure time: 28 d

Method: OECD Test Guideline 301B

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 4,5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

**Components:** 

Propan-2-ol:

Partition coefficient: n- : log Pow: 0,05

octanol/water

N-Methyl-2-pyrrolidone:

Partition coefficient: n- : log Pow: -0,46

octanol/water Method: OECD Test Guideline 107

Fluazuron:

Partition coefficient: n- : log Pow: 5,1

octanol/water

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-

octanol/water

: log Pow: 4

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Partition coefficient: n- : log Pow: 1,34

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

octanol/water Method: OECD Test Guideline 107

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1.800

Partition coefficient: n-

octanol/water

: log Pow: 5,1

### 12.4 Mobility in soil

### **Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ-

mental compartments

: log Koc: > 3,6

#### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

# 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or ex-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 8.0
 28.09.2024
 803738-00028
 Date of first issue: 12.07.2016

pose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or death. If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 1993
ADR : UN 1993
RID : UN 1993
IMDG : UN 1993
IATA : UN 1993

14.2 UN proper shipping name

**ADN** : FLAMMABLE LIQUID, N.O.S.

(Propan-2-ol)

**ADR** : FLAMMABLE LIQUID, N.O.S.

(Propan-2-ol)

RID : FLAMMABLE LIQUID, N.O.S.

(Propan-2-ol)

**IMDG** : FLAMMABLE LIQUID, N.O.S.

(Propan-2-ol, Fluazuron, abamectin (combination of avermec-

tin B1a and avermectin B1b) (ISO))

IATA : Flammable liquid, n.o.s.

(Propan-2-ol)

#### 14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 3
ADR : 3
RID : 3
IMDG : 3
IATA : 3

# 14.4 Packing group

ADN

Packing group : III
Classification Code : F1
Hazard Identification Number : 30
Labels : 3

**ADR** 

Packing group : III
Classification Code : F1
Hazard Identification Number : 30

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

Labels : 3
Tunnel restriction code : (D/E)

**RID** 

Packing group : III
Classification Code : F1
Hazard Identification Number : 30
Labels : 3

**IMDG** 

Packing group : III
Labels : 3
EmS Code : F-E, <u>S-E</u>

IATA (Cargo)

Packing instruction (cargo : 366

aircraft)

Packing instruction (LQ) : Y344
Packing group : III

Labels : Flammable Liquids

IATA (Passenger)

Packing instruction (passen: 355

ger aircraft)

Packing instruction (LQ) : Y344
Packing group : III

Labels : Flammable Liquids

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

**ADR** 

Environmentally hazardous : yes

**RID** 

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

# **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, Conditions of restriction for the following entries should be considered:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

mixtures and articles (Annex XVII)

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Number on list 3

Number on list 30: N-Methyl-2-

pyrrolidone

Number on list 71: N-Methyl-2-

pyrrolidone

Number on list 72: N-Methyl-2-

pyrrolidone

Number on list 75: If you intend to use this product as tattoo ink, please

contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation

(Annex XIV)

Regulation (EC) on substances that deplete the ozone

laver

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

N-Methyl-2-pyrrolidone

Not applicable

Not applicable

Not applicable

: Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

P5c FLAMMABLE LIQUIDS 5.000 t 50.000 t

E1 ENVIRONMENTAL 100 t 200 t HAZARDS

#### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

# **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H225 : Highly flammable liquid and vapour.

H300 : Fatal if swallowed.

H311 : Toxic in contact with skin. H315 : Causes skin irritation.

H317 : May cause an allergic skin reaction.
H319 : Causes serious eye irritation.

H330 : Fatal if inhaled.

H335 : May cause respiratory irritation.
H336 : May cause drowsiness or dizziness.
H341 : Suspected of causing genetic defects.

H360D : May damage the unborn child.

H361fd : Suspected of damaging fertility. Suspected of damaging the

unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H373 : May cause damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.
H412 : Harmful to aquatic life with long lasting effects.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation
Flam. Liq. : Flammable liquids
Muta. : Germ cell mutagenicity
Repr. : Reproductive toxicity

Skin Irrit. : Skin irritation
Skin Sens. : Skin sensitisation

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

2004/37/EC : Europe. Directive 2004/37/EC on the protection of workers

from the risks related to exposure to carcinogens or mutagens

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 8.0 28.09.2024 803738-00028 Date of first issue: 12.07.2016

at work

2009/161/EU : Europe. COMMISSION DIRECTIVE 2009/161/EU establishing

a third list of indicative occupational exposure limit values in implementation of Council Directive 98/24/EC and amending

Commission Directive 2000/39/EC

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

2004/37/EC / STEL : Short term exposure limit 2004/37/EC / TWA : Long term exposure limit 2009/161/EU / TWA : Limit Value - eight hours 2009/161/EU / STEL : Short term exposure limit FOR-2011-12-06-1358 / : Long term exposure limit

TWA

FOR-2011-12-06-1358 / : Short term exposure limit

**STEL** 

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory: LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Fluazuron / Abamectin Formulation

| Version | Revision Date: | SDS Number:  | Date of last issue: 06.07.2024  |
|---------|----------------|--------------|---------------------------------|
| 8.0     | 28.09.2024     | 803738-00028 | Date of first issue: 12.07.2016 |

| Classification of the mixture: |       | Classification procedure:           |
|--------------------------------|-------|-------------------------------------|
| Flam. Liq. 3                   | H226  | Based on product data or assessment |
| Acute Tox. 4                   | H332  | Calculation method                  |
| Skin Irrit. 2                  | H315  | Calculation method                  |
| Eye Irrit. 2                   | H319  | Calculation method                  |
| Skin Sens. 1                   | H317  | Calculation method                  |
| Muta. 2                        | H341  | Calculation method                  |
| Repr. 1B                       | H360D | Calculation method                  |
| STOT SE 3                      | H336  | Calculation method                  |
| STOT SE 3                      | H335  | Calculation method                  |
| STOT RE 2                      | H373  | Calculation method                  |
| Aquatic Acute 1                | H400  | Calculation method                  |
| Aquatic Chronic 1              | H410  | Calculation method                  |

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN